451 related articles for article (PubMed ID: 18950857)
1. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
[TBL] [Abstract][Full Text] [Related]
2. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
[TBL] [Abstract][Full Text] [Related]
3. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
[TBL] [Abstract][Full Text] [Related]
4. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
[TBL] [Abstract][Full Text] [Related]
5. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
[TBL] [Abstract][Full Text] [Related]
6. [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation].
Gu WY; Chen ZX; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):444-7. PubMed ID: 15854547
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
[TBL] [Abstract][Full Text] [Related]
8. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
[TBL] [Abstract][Full Text] [Related]
9. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study.
Østergaard M; Olesen LH; Hasle H; Kjeldsen E; Hokland P
Br J Haematol; 2004 Jun; 125(5):590-600. PubMed ID: 15147374
[TBL] [Abstract][Full Text] [Related]
10. [Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan].
Miyawaki S; Emi N; Mitani K; Oyashiki K; Kitamura K; Morishita T; Ogawa H; Komatsu N; Soma T; Tamaki T; Kosugi H; Ohnishi K; Mizoguchi H; Hiraoka A; Kodera Y; Ueda R; Morishima Y; Nakagawa M; Tobita T; Sugimoto K; Chiba S; Inoue N; Hamaguchi M; Koga D; Tamaki H; Naoe T; Sugiyama H; Takaku F
Rinsho Ketsueki; 2005 Dec; 46(12):1279-87. PubMed ID: 16447800
[TBL] [Abstract][Full Text] [Related]
11. Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia.
Spanaki A; Perdikogianni C; Linardakis E; Kalmanti M
Leuk Res; 2007 May; 31(5):639-42. PubMed ID: 16860864
[TBL] [Abstract][Full Text] [Related]
12. [Significance of monitoring WT1 mRNA levels of peripheral blood and bone marrow in acute myeloid leukemia].
Kitamura K; Nakano Y; Watamoto K; Koga D; Naoe T
Rinsho Ketsueki; 2010 Dec; 51(12):1748-55. PubMed ID: 21258184
[TBL] [Abstract][Full Text] [Related]
13. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects.
Paydas S; Tanriverdi K; Yavuz S; Disel U; Baslamisli F; Burgut R
Am J Hematol; 2005 Aug; 79(4):257-61. PubMed ID: 16044453
[TBL] [Abstract][Full Text] [Related]
14. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
Santamaría C; Chillón MC; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Ramos F; Bernal T; Queizán JA; Peñarrubia MJ; Giraldo P; San Miguel JF; Gonzalez M
Haematologica; 2008 Dec; 93(12):1797-805. PubMed ID: 18815192
[TBL] [Abstract][Full Text] [Related]
15. [Detection of WT1 expression in bone marrow of acute leukemia patients with real-time quantitative RT-PCR].
Gu WY; Chen ZX; Cao XS; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
Zhonghua Xue Ye Xue Za Zhi; 2004 Dec; 25(12):728-31. PubMed ID: 15730716
[TBL] [Abstract][Full Text] [Related]
16. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.
Lapillonne H; Renneville A; Auvrignon A; Flamant C; Blaise A; Perot C; Lai JL; Ballerini P; Mazingue F; Fasola S; Dehée A; Bellman F; Adam M; Labopin M; Douay L; Leverger G; Preudhomme C; Landman-Parker J
J Clin Oncol; 2006 Apr; 24(10):1507-15. PubMed ID: 16575000
[TBL] [Abstract][Full Text] [Related]
17. Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation.
Uzunel M; Ringdén O
Bone Marrow Transplant; 2004 Jan; 33(1):47-52. PubMed ID: 14704656
[TBL] [Abstract][Full Text] [Related]
18. Elevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukaemia.
Osborne D; Frost L; Tobal K; Liu Yin JA
Bone Marrow Transplant; 2005 Jul; 36(1):67-70. PubMed ID: 15908982
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
[TBL] [Abstract][Full Text] [Related]
20. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.
Boublikova L; Kalinova M; Ryan J; Quinn F; O'Marcaigh A; Smith O; Browne P; Stary J; McCann SR; Trka J; Lawler M
Leukemia; 2006 Feb; 20(2):254-63. PubMed ID: 16341043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]